Alexander T Cohen

List of Publications by Year
in descending order

171	22,233	53751 45	8384 147
papers	citations	h-index	g-index

173	173	173	11501
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study. Thrombosis and Haemostasis, 2022, 122, 646-656.	1.8	25
2	Inverse relationship between body mass index and risk of venous thromboembolism among medically ill hospitalized patients: Observations from the APEX trial. Thrombosis Research, 2022, 211, 63-69.	0.8	1
3	Direct Oral Anticoagulants for the Treatment of Cancer-Associated Venous Thromboembolism: A Latin American Perspective. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 107602962210829.	0.7	7
4	Identification of undiagnosed atrial fibrillation using a machine learning risk-prediction algorithm and diagnostic testing (PULsE-AI) in primary care: a multi-centre randomized controlled trial in England. European Heart Journal Digital Health, 2022, 3, 195-204.	0.7	8
5	Thirtyâ€day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for lifeâ€threatening direct oral anticoagulantâ€related bleeding. Journal of the American College of Emergency Physicians Open, 2022, 3, e12655.	0.4	10
6	Recurrent venous thromboembolism and major bleeding in patients with localised, locally advanced or metastatic cancer: an analysis of the Caravaggio study. European Journal of Cancer, 2022, 165, 136-145.	1.3	11
7	Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials. Circulation, 2022, 145, 1471-1479.	1.6	6
8	Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease. Thrombosis and Haemostasis, 2022, 122, 926-938.	1.8	16
9	Assessment of the burden of disease for patients with peripheral artery disease undergoing revascularization in England. Vascular Medicine, 2022, 27, 440-449.	0.8	2
10	Identification of undiagnosed atrial fibrillation using a machine learning risk prediction algorithm and diagnostic testing (PULsE-AI) in primary care: cost-effectiveness of a screening strategy evaluated in a randomized controlled trial in England. Journal of Medical Economics, 2022, 25, 974-983.	1.0	7
11	Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data Analysis. Thrombosis and Haemostasis, 2021, 121, 383-395.	1.8	25
12	Direct Oral Anticoagulant Concentrations in Obese and High Body Weight Patients: A Cohort Study. Thrombosis and Haemostasis, 2021, 121, 224-233.	1.8	35
13	Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients. Journal of the American Heart Association, 2021, 10, e019459.	1.6	30
14	Efficacy, Safety, and Exposure of Apixaban in Patients with High Body Weight or Obesity and Venous Thromboembolism: Insights from AMPLIFY. Advances in Therapy, 2021, 38, 3003-3018.	1.3	19
15	Recommendations for Research Assessing Outcomes for Patients With Anticoagulant-Related Intracerebral Bleeds. Stroke, 2021, 52, 1520-1526.	1.0	3
16	Double trouble for cancer patients. European Heart Journal, 2021, 42, 2308-2310.	1.0	4
17	Effectiveness and safety of apixaban, LMWH, and warfarin among high-risk subgroups of VTE patients with active cancer. Current Medical Research and Opinion, 2021, 37, 1467-1482.	0.9	3
18	SARS-CoV-2 Vaccine and Thrombosis: An Expert Consensus on Vaccine-Induced Immune Thrombotic Thrombocytopenia. Thrombosis and Haemostasis, 2021, 121, 982-991.	1.8	50

#	Article	IF	Citations
19	Sex-specific differences in the presentation, clinical course, and quality of life of patients with acute venous thromboembolism according to baseline risk factors. Insights from the PREFER in VTE. European Journal of Internal Medicine, 2021, 88, 43-51.	1.0	10
20	Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study. Journal of Thrombosis and Haemostasis, 2021, 19, 2751-2759.	1.9	18
21	Effectiveness and Safety of Apixaban Versus Warfarin Among Older Patients with Venous Thromboembolism with Different Demographics and Socioeconomic Status. Advances in Therapy, 2021, 38, 5519-5533.	1.3	7
22	Patient-reported outcomes associated with changing to rivaroxaban for the treatment of cancer-associated venous thromboembolism â€“ The COSIMO study. Thrombosis Research, 2021, 206, 1-4.	0.8	10
23	Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity. Journal of Clinical Medicine, 2021, 10, 200.	1.0	21
24	Cancerâ€Associated ThrOmboSIs â€“ Patientâ€Reported OutcoMes With RivarOxaban (COSIMO) â€“ Baseline characteristics and clinical outcomes. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12604.	1.0	3
25	Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. Haematologica, 2021, , .	1.7	0
26	Budget impact analysis of betrixaban for venous thromboembolism prophylaxis in nonsurgical patients with acute medical illness in the United Kingdom. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 20, 259-267.	0.7	1
27	Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial. Journal of Thrombosis and Thrombolysis, 2020, 49, 214-219.	1.0	6
28	Temporal trends in the incidence, treatment patterns, and outcomes of coronary artery disease and peripheral artery disease in the UK, 2006â€“2015. European Heart Journal, 2020, 41, 1636-1649.	1.0	36
29	ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries. European Journal of Internal Medicine, 2020, 82, 48-55.	1.0	5
30	ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3Âmonths. Thrombosis Research, 2020, 196, 297-304.	0.8	5
31	Identification of undiagnosed atrial fibrillation patients using a machine learning risk prediction algorithm and diagnostic testing (PULsE-AI): Study protocol for a randomised controlled trial. Contemporary Clinical Trials, 2020, 99, 106191.	0.8	14
32	Prevention of venous thromboembolism in ambulatory patients with cancer. ESMO Open, 2020, 5, e000948.	2.0	16
33	Impact of Patient Characteristics on Treatment Outcomes in Symptomatic Venous Thromboembolism: Results of HOKUSAI-VTE Randomized Trial Analysis. TH Open, 2020, 04, e245-e254.	0.7	0
34	Derivation and Validation of a Prediction Model for Venous Thromboembolism in Primary Care. Thrombosis and Haemostasis, 2020, 120, 692-701.	1.8	9
35	Variation in the Association between Antineoplastic Therapies and Venous Thromboembolism in Patients with Active Cancer. Thrombosis and Haemostasis, 2020, 120, 847-856.	1.8	20
36	Prevention of Venous Thromboembolism in Hospitalized Medically Ill Patients: A U.S. Perspective. Thrombosis and Haemostasis, 2020, 120, 924-936.	1.8	12

#	Article	IF	Citations
37	Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. New England Journal of Medicine, 2020, 382, 1599-1607.	13.9	658
38	Bleeding and recurrent VTE with apixaban vs warfarin as outpatient treatment: time-course and subgroup analyses. Blood Advances, 2020, 4, 432-439.	2.5	11
39	Prediction of significant bleeding during vitamin K antagonist treatment for venous thromboembolism in outpatients. British Journal of Haematology, 2020, 189, 524-533.	1.2	8
40	Netâ€clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more. Journal of Thrombosis and Haemostasis, 2019, 17, 2089-2098.	1.9	5
41	Effectiveness and safety of betrixaban extended prophylaxis for venous thromboembolism compared with standard-duration prophylaxis intervention in acute medically ill patients: a systematic literature review and network meta-analysis. Journal of Medical Economics, 2019, 22, 1063-1072.	1.0	2
42	Predicting atrial fibrillation in primary care using machine learning. PLoS ONE, 2019, 14, e0224582.	1.1	88
43	Magnitude of Venous Thromboembolism Risk in US Hospitals: Impact of Evolving National Guidelines for Prevention of Venous Thromboembolism. American Journal of Medicine, 2019, 132, 588-595.	0.6	4
44	Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial. TH Open, 2019, 03, e103-e108.	0.7	1
45	Anticoagulant selection for patients with VTEâ€”Evidence from a systematic literature review of network meta-analyses. Pharmacological Research, 2019, 143, 166-177.	3.1	17
46	Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based study. Haematologica, 2019, 104, e474-e477.	1.7	1
47	Health-related quality of life and mortality in patients with pulmonary embolism: a prospective cohort study in seven European countries. Quality of Life Research, 2019, 28, 2111-2124.	1.5	38
48	Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. New England Journal of Medicine, 2019, 380, 1326-1335.	13.9	687
49	Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAMe-TT2-R2 Score: An Analysis of Hokusai-VTE. Thrombosis and Haemostasis, 2019, 119, 675-684.	1.8	9
50	Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy. Intensive Care Medicine, 2019, 45, 477-487.	3.9	17
51	Rivaroxaban and the EINSTEIN clinical trial programme. Blood Coagulation and Fibrinolysis, 2019, 30, 85-95.	0.5	18
52	Cost-Effectiveness of Betrixaban Compared with Enoxaparin for Venous Thromboembolism Prophylaxis in Nonsurgical Patients with Acute Medical Illness in the United States. Pharmacoeconomics, 2019, 37, 701-714.	1.7	10
53	Comparison of quality of life measurements: EQ-5D-5L versus disease/treatment-specific measures in pulmonary embolism and deep vein thrombosis. Quality of Life Research, 2019, 28, 1155-1177.	1.5	9
54	Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial. American Journal of Hematology, 2019, 94, 21-28.	2.0	50

#	Article	IF	Citations
55	Is there a role for low-dose DOACs as prophylaxis?. Hematology American Society of Hematology Education Program, 2019, 2019, 187-193.	0.9	4
56	Heparin for the prevention of venous thromboembolism in acutely ill medical patients (excluding) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.5	76
57	Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy. American Journal of Medicine, 2018, 131, 972.e1-972.e7.	0.6	29
58	Pulmonary embolism in Europe - Burden of illness in relationship to healthcare resource utilization and return to work. Thrombosis Research, 2018, 170, 181-191.	0.8	29
59	Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients. Circulation, 2018, 137, 91-94.	1.6	27
60	Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients. American Heart Journal, 2018, 198, 84-90.	1.2	19
61	Clinical Impact and Course of Anticoagulant-Related Major Bleeding in Cancer Patients. Thrombosis and Haemostasis, 2018, 118, 174-181.	1.8	11
62	Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study. Thrombosis Journal, 2018, 16, 9.	0.9	15
63	Direct Oral Anticoagulants for Pulmonary Embolism: Importance of Anatomical Extent. TH Open, 2018, 02, e1-e7.	0.7	5
64	Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial. Journal of Thrombosis and Thrombolysis, 2018, 45, 1-8.	1.0	14
65	Primary thromboembolic prevention in multiple myeloma patients: An exploratory meta-analysis on aspirin use. Seminars in Hematology, 2018, 55, 182-184.	1.8	6
66	Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial. Thrombosis and Haemostasis, 2018, 118, 2046-2052.	1.8	48
67	Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice. Thrombosis and Haemostasis, 2018, 118, 1951-1961.	1.8	34
68	The impact of co-morbidity on the disease burden of VTE. Journal of Thrombosis and Thrombolysis, 2018, 46, 507-515.	1.0	9
69	COSIMO â€“ patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study. Thrombosis Journal, 2018, 16, 21.	0.9	20
70	Risk of recurrent venous thromboembolism according to baseline risk factor profiles. Blood Advances, 2018, 2, 788-796.	2.5	71
71	Association of D-dimer Levels with Clinical Event Rates and the Efficacy of Betrixaban versus Enoxaparin in the APEX Trial. TH Open, 2018, 02, e16-e24.	0.7	8
72	Cost-effectiveness of edoxaban compared to warfarin for the treatment and secondary prevention of venous thromboembolism in the UK. Journal of Market Access & Health Policy, 2018, 6, 1495974.	0.8	4

#	Article	IF	Citations
73	Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin. Thrombosis Research, 2018, 168, 121-129.	0.8	11
74	Extended thromboprophylaxis with betrixaban: a new standard for acute medically ill patients. European Heart Journal Supplements, 2018, 20, E1-E2.	0.0	8
75	Apixaban versus Dalteparin for the Treatment of Acute Venous Thromboembolism in Patients with Cancer: The Caravaggio Study. Thrombosis and Haemostasis, 2018, 118, 1668-1678.	1.8	121
76	Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences. BMC Health Services Research, 2017, 17, 74.	0.9	14
77	When academic research organizations and clinical research organizations disagree: Processes to minimize discrepancies prior to unblinding of randomized trials. American Heart Journal, 2017, 189, 1-8.	1.2	14
78	Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. New England Journal of Medicine, 2017, 376, 1211-1222.	13.9	577
79	The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous) Tj ETQq1 1 0.784314 rgBT /Ove Journal, 2017, 185, 93-100.	1.2	48
80	Competing risk analysis in a large cardiovascular clinical trial: An <scp>APEX</scp> substudy. Pharmaceutical Statistics, 2017, 16, 445-450.	0.7	8
81	N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy. Journal of Thrombosis and Thrombolysis, 2017, 44, 457-465.	1.0	11
82	The utility of thromboelastography and thrombin generation in assessing the prothrombotic state of adults with sickle cell disease. Thrombosis Research, 2017, 158, 113-120.	0.8	6
83	Comparison of Fatal or Irreversible Events With Extendedâ€Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. Journal of the American Heart Association, 2017, 6, .	1.6	40
84	The role of heparin lead-in in the real-world management of acute venous thromboembolism: The PREFER in VTE registry. Thrombosis Research, 2017, 157, 181-188.	0.8	10
85	The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification. TH Open, 2017, 01, e56-e65.	0.7	94
86	Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients. Circulation, 2017, 135, 648-655.	1.6	61
87	Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials. Thrombosis Research, 2017, 149, 29-37.	0.8	14
88	Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial. Thrombosis and Haemostasis, 2017, 117, 2389-2395.	1.8	22
89	Cancer-associated venous thromboembolism: Burden, mechanisms, and management. Thrombosis and Haemostasis, 2017, 117, 219-230.	1.8	337
90	Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study. Thrombosis and Haemostasis, 2017, 117, 2406-2414.	1.8	8

#	Article	IF	Citations
91	The management of acute venous thromboembolism in clinical practice. Thrombosis and Haemostasis, 2017, 117, 1326-1337.	1.8	74
92	Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. Thrombosis and Haemostasis, 2017, 117, 57-65.	1.8	193
93	Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. Thrombosis and Haemostasis, 2016, 115, 809-816.	1.8	16
94	Extended anticoagulation with apixaban reduces hospitalisations in patients with venous thromboembolism. Thrombosis and Haemostasis, 2016, 115, 161-168.	1.8	13
95	Betrixaban in Acutely Ill Medical Patients. New England Journal of Medicine, 2016, 375, e50.	13.9	3
96	Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. New England Journal of Medicine, 2016, 375, 534-544.	13.9	379
97	Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology,the, 2016, 3, e437-e445.	2.2	29
98	Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. New England Journal of Medicine, 2016, 375, 1131-1141.	13.9	692
99	Treatment of venous thromboembolism with rivaroxaban in relation to body weight. Thrombosis and Haemostasis, 2016, 116, 739-746.	1.8	58
100	Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE. Chest, 2016, 150, 1059-1068.	0.4	24
101	Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematology,the, 2016, 3, e228-e236.	2.2	55
102	Extended-Duration Thromboprophylaxis Among Acute Medically Ill Patients. Journal of Cardiovascular Pharmacology and Therapeutics, 2016, 21, 227-232.	1.0	9
103	Direct Oral Anticoagulants and Their Use in Treatment and Secondary Prevention of Acute Symptomatic Venous Thromboembolism. Clinical and Applied Thrombosis/Hemostasis, 2016, 22, 209-221.	0.7	5
104	Why do we need observational studies of everyday patients in the real-life setting?: TableÂ1. European Heart Journal Supplements, 2015, 17, D2-D8.	0.0	101
105	The management of acute venous thromboembolism in clinical practice â€“ study rationale and protocol of the European PREFER in VTE Registry. Thrombosis Journal, 2015, 13, 41.	0.9	40
106	Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Thrombosis and Haemostasis, 2015, 114, 645-650.	1.8	48
107	VTE primary prevention, including hospitalised medical and orthopaedic surgical patients. Thrombosis and Haemostasis, 2015, 113, 1216-1223.	1.8	11
108	Use of Prestudy Heparin Did Not Influence the Efficacy and Safety of Rivaroxaban in Patients Treated for Symptomatic Venous Thromboemâ€bolism in the EINSTEIN DVT and EINSTEIN PE Studies. Academic Emergency Medicine, 2015, 22, 142-149.	0.8	13

#	Article	IF	Citations
109	Treating pulmonary embolism in Pacific Asia with direct oral anticoagulants. Thrombosis Research, 2015, 136, 196-207.	0.8	5
110	Venous thromboembolism prevention and treatment: expanding the rivaroxaban knowledge base with real-life data. European Heart Journal Supplements, 2015, 17, D32-D41.	0.0	10
111	Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deepâ€Vein Thrombosis as Firstâ€Line Therapy (AMPLIFY) Trial. Journal of the American Heart Association, 2015, 4, .	1.6	27
112	Recognition of biomarker identified high-risk patients in the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban study resulting in a protocol amendment. American Heart Journal, 2015, 169, 186-187.	1.2	9
113	Impact of Thromboprophylaxis across the US Acute Care Setting. PLoS ONE, 2015, 10, e0121429.	1.1	6
114	Excellence, quality and limitations of the <scp>NICE</scp> venous thromboembolism score tool: how can it be improved?. British Journal of Haematology, 2014, 167, 702-704.	1.2	4
115	The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study. American Heart Journal, 2014, 167, 335-341.	1.2	81
116	Managing pulmonary embolism from presentation to extended treatment. Thrombosis Research, 2014, 133, 139-148.	0.8	41
117	Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematology,the, 2014, 1, e37-e46.	2.2	244
118	Phase III Trials of New Oral Anticoagulants in the Acute Treatment and Secondary Prevention of VTE: Comparison and Critique of Study Methodology and Results. Advances in Therapy, 2014, 31, 473-493.	1.3	32
119	Predicting the Risk of Venous Thromboembolism in Patients Hospitalized With Heart Failure. Circulation, 2014, 130, 410-418.	1.6	53
120	Epidemiology of first and recurrent venous thromboembolism: A population-based cohort study in patients without active cancer. Thrombosis and Haemostasis, 2014, 112, 255-263.	1.8	156
121	Time in Therapeutic Range (TTR) and Relative Efficacy and Safety of Treatment with Apixaban or Enoxaparin/Warfarin for Acute Symptomatic Venous Thromboembolism: An Analysis of the Amplify Trial Data. Blood, 2014, 124, 1543-1543.	0.6	4
122	NOACs for thromboprophylaxis in medical patients. Best Practice and Research in Clinical Haematology, 2013, 26, 183-190.	0.7	1
123	Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal, 2013, 11, 21.	0.9	471
124	Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients. New England Journal of Medicine, 2013, 368, 513-523.	13.9	524
125	Apixaban for Extended Treatment of Venous Thromboembolism. New England Journal of Medicine, 2013, 368, 699-708.	13.9	1,116
126	Oral Apixaban for the Treatment of Acute Venous Thromboembolism. New England Journal of Medicine, 2013, 369, 799-808.	13.9	1,915

#	Article	IF	Citations
127	Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients. New England Journal of Medicine, 2013, 368, 1944-1946.	13.9	28
128	Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. New England Journal of Medicine, 2012, 366, 1287-1297.	13.9	2,080
129	The Efficacy and Safety of Pharmacological Prophylaxis of Venous Thromboembolism Following Elective Knee or Hip Replacement. Clinical and Applied Thrombosis/Hemostasis, 2012, 18, 611-627.	0.7	27
130	How I manage venous thromboembolism risk in hospitalized medical patients. Blood, 2012, 120, 1562-1569.	0.6	23
131	The use of rivaroxaban for short- and long-term treatment of venous thromboembolism. Thrombosis and Haemostasis, 2012, 107, 1035-1043.	1.8	25
132	Thromboprophylaxis in non-surgical cancer patients. Thrombosis Research, 2012, 129, S137-S145.	0.8	14
133	Long-term benefits of preventing venous thromboembolic events. Current Medical Research and Opinion, 2012, 28, 877-889.	0.9	13
134	Managing venous thromboembolism in Asia: Winds of change in the era of new oral anticoagulants. Thrombosis Research, 2012, 130, 291-301.	0.8	16
135	Two Doses of Apixaban for the Extended Treatment of Venous Thromboembolism. Blood, 2012, 120, LBA-1-LBA-1.	0.6	4
136	Prevention of VTE in women with cancer. Thrombosis Research, 2011, 127, S5-S8.	0.8	27
137	The MAGELLAN Study: An Analysis of Outcomes Utilizing D-Dimer. Blood, 2011, 118, 542-542.	0.6	3
138	Venous Thromboembolism Risk and Prophylaxis in the Acute Care Hospital Setting (ENDORSE Survey). Annals of Surgery, 2010, 251, 330-338.	2.1	93
139	Asia-Pacific Thrombosis Advisory Board consensus paper on prevention of venous thromboembolism after major orthopaedic surgery. Thrombosis and Haemostasis, 2010, 104, 919-930.	1.8	30
140	Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients. Thrombosis and Haemostasis, 2010, 103, 736-748.	1.8	86
141	Improving Practices in US Hospitals to Prevent Venous Thromboembolism: Lessons from ENDORSE. American Journal of Medicine, 2010, 123, 1099-1106.e8.	0.6	21
142	VTE prophylaxis for the medical patient: where do we stand? â€“ A focus on cancer patients. Thrombosis Research, 2010, 125, S21-S29.	0.8	20
143	Oral Rivaroxaban for Symptomatic Venous Thromboembolism. New England Journal of Medicine, 2010, 363, 2499-2510.	13.9	2,807
144	Will a once-weekly anticoagulant for the treatment and secondary prevention of thromboembolism improve adherence?. Thrombosis and Haemostasis, 2009, 101, 422-427.	1.8	10

#	Article	IF	Citations
145	Will a once-weekly anticoagulant for the treatment and secondary prevention of thromboembolism improve adherence?. Thrombosis and Haemostasis, 2009, 101, 422-7.	1.8	1
146	Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet, The, 2008, 371, 387-394.	6.3	1,258
147	A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einsteinâ€“DVT Dose-Ranging Study. Blood, 2008, 112, 2242-2247.	0.6	316
148	Impact of Surgery Type and Co-Morbidities on Venous Thromboembolism prophylaxis Practices in Patients Undergoing Major Surgical Procedures in Acute Care Hospitals Worldwide: A Subanalysis of Data from the ENDORSE Survey. Blood, 2008, 112, 171-171.	0.6	5
149	An Adaptive-Design Dose-Ranging Study of PD 0348292, a New Oral Factor Xa Inhibitor, for Thromboprophylaxis after Total Knee Replacement Surgery.. Blood, 2008, 112, 980-980.	0.6	9
150	Venous Thromboembolism Risk and Prophylaxis Practices in Surgical Patients with Active Cancer: Findings from the Global ENDORSE Survey.. Blood, 2008, 112, 984-984.	0.6	1
151	The Unmet Need for Extended Thromboprophylaxis in Acutely Ill Medical Patients: The Findings of IMPROVE, ENDORSE and EXCLAIM.. Blood, 2008, 112, 1981-1981.	0.6	3
152	Thromboprophylaxis with dalteparin in medical patients: which patients benefit?. Vascular Medicine, 2007, 12, 123-127.	0.8	47
153	Venous thromboembolism (VTE) in Europe. Thrombosis and Haemostasis, 2007, 98, 756-764.	1.8	1,100
154	Estimated annual numbers of US acuteâ€care hospital patients at risk for venous thromboembolism. American Journal of Hematology, 2007, 82, 777-782.	2.0	257
155	Venous Thromboembolic Risk and Suboptimal Prophylaxis in the US Acute Hospital Care Setting: Findings from the ENDORSE Study.. Blood, 2007, 110, 1858-1858.	0.6	0
156	Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thrombosis and Haemostasis, 2007, 98, 756-64.	1.8	531
157	Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ: British Medical Journal, 2006, 332, 325-329.	2.4	723
158	Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. Thrombosis and Haemostasis, 2005, 93, 76-79.	1.8	151
159	Efficacy and Safety of Fixed Low-Dose Dalteparin in Preventing Venous Thromboembolism Among Obese or Elderly Hospitalized Patients. Archives of Internal Medicine, 2005, 165, 341.	4.3	101
160	Pharmacological Prevention of Venous Thromboembolism in Medical Patients at Risk. American Journal of Cardiovascular Drugs, 2005, 5, 409-415.	1.0	4
161	Estimated Annual Number of Incident and Recurrent, Non-Fatal and Fatal Venous Thromboembolism (VTE) Events in the US.. Blood, 2005, 106, 910-910.	0.6	224
162	Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thrombosis and Haemostasis, 2005, 94, 750-9.	1.8	173

#	Article	IF	Citations
163	Risk Factors for Venous Thromboembolism in Hospitalized Patients With Acute Medical Illness. Archives of Internal Medicine, 2004, 164, 963.	4.3	395
164	Randomized, Placebo-Controlled Trial of Dalteparin for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients. Circulation, 2004, 110, 874-879.	1.6	856
165	Epidemiology of post-operative venous thromboembolismin asian countries. International Journal of Angiology, 2004, 13, 101-108.	0.2	20
166	Correlation of Plasma Coagulation Parameters With Thromboprophylaxis, Patient Characteristics, and Outcome in the MEDENOX Study. Archives of Pathology and Laboratory Medicine, 2004, 128, 519-526.	1.2	36
167	Fatal Pulmonary Embolism and Cancer - a Post Mortem Study.. Blood, 2004, 104, 2593-2593.	0.6	0
168	Prevention of venous thromboembolism in medical patients with enoxaparin. Blood Coagulation and Fibrinolysis, 2003, 14, 341-346.	0.5	224
169	Discoveries in Thrombosis Care for Medical Patients. Seminars in Thrombosis and Hemostasis, 2002, 28, 013-018.	1.5	13
170	Prophylaxis of venous thromboembolism in medical patients. Current Opinion in Pulmonary Medicine, 2001, 7, 332-337.	1.2	23
171	The Changing Pattern of Venous Thromboembolic Disease. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 1996, 26, 65-71.	0.5	39